MC
EW icon

Moors & Cabot’s Edwards Lifesciences EW Stock Holding History

Moors & Cabot’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$2K – 892
2024
Q1 		$2K Buy
+100
New +$8.4K ﹤0.01% 904
2023
Q3 		– Hold
0
– -$1.83K – 841
2023
Q2 		– Hold
0
– – – 839
2023
Q1 		– Hold
0
– – – 838
2021
Q3 		– Sell
-500
Closed -$13K – 883
2021
Q2 		$13K Hold
500
– – ﹤0.01% 806
2021
Q1 		$5K Buy
+500
New +$42.3K ﹤0.01% 764

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Moors & Cabot's EW Position: Q2 2026 in Review

Moors & Cabot increased its Edwards Lifesciences (EW) stake by 1.6% in Q2 2026, buying an estimated $71.4K and bringing the position to 55,165 shares worth $4.99M. The position accounts for 0.19% of the portfolio, ranked #105.

Moors & Cabot first reported a position in EW in Q2 2014 and has held it in 49 quarters since. The position peaked at $6.65M in Q4 2021. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Moors & Cabot held 55,165 shares of Edwards Lifesciences worth $4.99M as of Q2 2026.
  • Moors & Cabot bought 852 Edwards Lifesciences shares in Q2 2026, an estimated $71.4K.
  • Edwards Lifesciences made up 0.19% of Moors & Cabot's portfolio in Q2 2026, its #105 holding.
  • Moors & Cabot first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 49 quarters since.
  • Moors & Cabot's Edwards Lifesciences position peaked at $6.65M in Q4 2021.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.